The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide. Extensive enhancement of glycolysis and reprogramming of lipid metabolism are both associated with the development and progression of PDAC. Previous studies have suggested that various gene signatures could convey prognostic information about PDAC. However, the use of these signatures has some limitations, perhaps because of a lack of knowledge regarding the genetic and energy supply backgrounds of PDAC. Therefore, we conducted multi-mRNA analysis based on metabolic reprogramming to identify novel signatures for accurate prognosis prediction in PDAC patients. In this study, a three-gene signature comprising MET, ENO3 and CD36 was established to predict the overall survival of PDAC patients. The three-g

SUBMITTER: Tan Z 

PROVIDER: S-EPMC7762467 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature